Beijing Dongxuli Pharmaceutical Technology

Beijing Dongxuli Pharmaceutical Technology is a clinical-stage biotechnology company based in Beijing, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company primarily focuses on oncology, with a specific emphasis on the mechanism of synthetic lethality to address unmet needs in cancer treatment. Its lead candidate, DXL-001, is a Poly (ADP-ribose) polymerase (PARP) inhibitor currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. Beyond its lead program, the company is advancing a pipeline of targeted therapies aimed at various oncogenic drivers. Dongxuli leverages its internal research capabilities to transition candidates from discovery through to clinical proof-of-concept.